Analysts Offer Insights on Healthcare Companies: Enliven Therapeutics (ELVN), Molina Healthcare (MOH) and Aldeyra Therapeutics (ALDX)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Enliven Therapeutics (ELVN), Molina Healthcare (MOH) and Aldeyra Therapeutics (ALDX).

Claim 55% Off TipRanks

• Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
• Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Enliven Therapeutics (ELVN)

In a report released today, Robert Burns from H.C. Wainwright reiterated a Buy rating on Enliven Therapeutics, with a price target of $56.00. The company’s shares closed last Friday at $40.75.

According to TipRanks.com, Burns is a 5-star analyst with an average return of 20.5% and a 47.8% success rate. Burns covers the Healthcare sector, focusing on stocks such as BridgeBio Oncology Therapeutics, Black Diamond Therapeutics, and ArriVent BioPharma, Inc. ;'>

Currently, the analyst consensus on Enliven Therapeutics is a Strong Buy with an average price target of $53.33, which is a 28.3% upside from current levels. In a report issued on April 27, Clear Street also maintained a Buy rating on the stock with a $55.00 price target.

See the top stocks recommended by analysts >>

Molina Healthcare (MOH)

In a report released today, Erin Wright from Morgan Stanley maintained a Hold rating on Molina Healthcare, with a price target of $146.00. The company’s shares closed last Friday at $185.94.

According to TipRanks.com, Wright is a 5-star analyst with an average return of 14.4% and a 63.3% success rate. Wright covers the Healthcare sector, focusing on stocks such as BrightSpring Health Services, Inc., Elanco Animal Health, and Option Care Health. ;'>

Currently, the analyst consensus on Molina Healthcare is a Hold with an average price target of $165.23, a -14.4% downside from current levels. In a report issued on April 27, Truist Financial also maintained a Hold rating on the stock with a $180.00 price target.

Aldeyra Therapeutics (ALDX)

H.C. Wainwright analyst Matthew Caufield reiterated a Hold rating on Aldeyra Therapeutics today and set a price target of $2.00. The company’s shares closed last Friday at $1.73.

According to TipRanks.com, Caufield is a 5-star analyst with an average return of 13.9% and a 44.1% success rate. Caufield covers the Healthcare sector, focusing on stocks such as Mineralys Therapeutics, Inc., 4D Molecular Therapeutics, and Phathom Pharmaceuticals. ;'>

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Aldeyra Therapeutics with a $5.50 average price target, a 223.5% upside from current levels. In a report issued on May 2, TipRanks – OpenAI also reiterated a Hold rating on the stock with a $1.50 price target.

Read More on ELVN:

Disclaimer & DisclosureReport an Issue

• Enliven price target raised to $59 from $41 at Goldman Sachs
• Phil Nadeau Reiterates Buy on Enliven, Citing Strong ELVN-001 Early Data, Clear Pivotal Path, and Solid Cash Runway to 2029
• Needham’s Boris Peaker Reiterates Buy on Enliven, Citing Strong ELVN-001 Efficacy in CML and Pivotal Phase 3 ENABLE-2 Catalyst Pathway
• Enliven reports Q1 EPS (38c) vs. (57c) last year
• Merck comments on TERN-701 positive for Enliven’s ELVN-001, says Mizuho